Globally, some of the key players such as Novartis (pelacarsen), Recardio (dutogliptin), Idorsia Pharmaceuticals (selatogrel), Boehringer Ingelheim and Eli Lilly and Company (JARDIANCE), Amgen (olpasiran), Mitsubishi Chemical Group (CL2020), and others are evaluating their lead candidates in different stages of clinical development.
DelveInsight’s “Myocardial Infarction Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Myocardial Infarction market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Myocardial Infarction market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Myocardial Infarction: An Overview
Myocardial Infarction (MI), commonly known as a heart attack, occurs when blood flow declines or stops in a part of the heart, triggering damage to the heart muscle. Acute myocardial infarction (AMI), a common manifestation of CVD in the elderly, carries an increased risk of mortality, morbidity, and excess costs. Currently, there are multiple effective management options following myocardial infarction, and guidelines recommend lifelong pharmaceutical prevention with beta-blockers, ACE inhibitors or angiotensin II receptor blockers, acetylsalicylic acid, and statins if not contraindicated.
Myocardial Infarction Market Key Facts
The total Myocardial Infarction market size in the 7MM is USD 21,477 million in 2021 and is projected to increase during the forecast period (2022-2032)
The Myocardial Infarction market in 7MM will increase at a CAGR of 1.61% due to increasing awareness of the disease and the launch of the emerging therapy
Among EU4 countries, Germany accounts for the maximum market size in 2021, while Spain occupied the bottom of the ladder in 2021
The total Myocardial Infarction diagnosed prevalent cases in the 7MM were approximately 15 million in 2021 and are projected to increase during the forecasted period.
The total diagnosed prevalent cases of Myocardial Infarction in the United States were around 8 million in 2021.
The United States contributed to the largest prevalent population of MI, acquiring ~52% of the 7MM in 2021. Whereas EU4 and the UK, and Japan accounted for around 36% and 11% of the total population share, respectively, in 2021
Among the EU4 countries, Germany accounted for the largest number of diagnosed Myocardial Infarction cases, followed by France, whereas Spain accounted for the lowest number of cases in 2021
Myocardial Infarction Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Myocardial Infarction market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Myocardial Infarction market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Myocardial Infarction Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
Myocardial Infarction Drugs Uptake and Pipeline Development Activities
The drugs’ uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myocardial Infarction market or expected to get launched during the study period. The analysis covers the Myocardial Infarction market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Myocardial Infarction pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Myocardial Infarction Market Will Evolve and Grow by 2032 @
The Leading Companies in the Myocardial Infarction Therapeutics Market Include:
Eli Lilly and Company
Mitsubishi Chemical Group
And Many Others
Myocardial Infarction Drugs Covered in the Report Include:
FARXIGA/FORXIGA (dapagliflozin): AstraZeneca
JARDIANCE (empagliflozin): Boehringer Ingelheim and Eli Lilly and Company
INSPRA (eplerenone): Pfizer
PLAVIX (clopidogrel bisulfate): Sanofi-Aventis/Bristol-Myers Squibb
BRILINTA (ticagrelor): AstraZeneca
PRALUENT (alirocumab): Regeneron/Sanofi
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Myocardial Infarction Competitive Intelligence Analysis
4. Myocardial Infarction Market Overview at a Glance
5. Myocardial Infarction Disease Background and Overview
6. Myocardial Infarction Patient Journey
7. Myocardial Infarction Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Myocardial Infarction Treatment Algorithm, Current Treatment, and Medical Practices
9. Myocardial Infarction Unmet Needs
10. Key Endpoints of Myocardial Infarction Treatment
11. Myocardial Infarction Marketed Products
12. Myocardial Infarction Emerging Drugs and Latest Therapeutic Advances
13. Myocardial Infarction Seven Major Market Analysis
14. Attribute Analysis
15. Myocardial Infarction Market Outlook (In US, EU5, and Japan)
16. Myocardial Infarction Access and Reimbursement Overview
17. KOL Views on the Myocardial Infarction Market
18. Myocardial Infarction Market Drivers
19. Myocardial Infarction Market Barriers
21. DelveInsight Capabilities
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Other Trending Healthcare Reports By DelveInsight
Myocardial Infarction Pipeline Insight
“Myocardial Infarction – Pipeline Insight, 2023” report provides comprehensive insights about 60+ companies and 62+ drugs in the Myocardial Infarction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States